Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPX NASDAQ:DNLI NASDAQ:MESO NASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPXCompass Therapeutics$3.67-0.8%$3.27$1.27▼$4.08$507.50M1.481.41 million shs2.12 million shsDNLIDenali Therapeutics$15.22-1.3%$14.42$10.57▼$33.33$2.23B1.31.54 million shs1.67 million shsMESOMesoblast$17.32-5.9%$15.48$7.09▼$22.00$2.22B2.3275,952 shs299,419 shsRXRXRecursion Pharmaceuticals$5.53+0.7%$5.10$3.79▼$12.36$2.40B0.9125.17 million shs34.26 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPXCompass Therapeutics0.00%-1.07%+7.56%+40.15%+91.71%DNLIDenali Therapeutics0.00%+10.54%-0.06%+8.21%-46.14%MESOMesoblast0.00%+16.08%+27.94%+74.83%+70.31%RXRXRecursion Pharmaceuticals0.00%+16.31%+19.09%+11.36%-10.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPXCompass Therapeutics$3.67-0.8%$3.27$1.27▼$4.08$507.50M1.481.41 million shs2.12 million shsDNLIDenali Therapeutics$15.22-1.3%$14.42$10.57▼$33.33$2.23B1.31.54 million shs1.67 million shsMESOMesoblast$17.32-5.9%$15.48$7.09▼$22.00$2.22B2.3275,952 shs299,419 shsRXRXRecursion Pharmaceuticals$5.53+0.7%$5.10$3.79▼$12.36$2.40B0.9125.17 million shs34.26 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPXCompass Therapeutics0.00%-1.07%+7.56%+40.15%+91.71%DNLIDenali Therapeutics0.00%+10.54%-0.06%+8.21%-46.14%MESOMesoblast0.00%+16.08%+27.94%+74.83%+70.31%RXRXRecursion Pharmaceuticals0.00%+16.31%+19.09%+11.36%-10.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPXCompass Therapeutics 2.91Moderate Buy$13.10256.95% UpsideDNLIDenali Therapeutics 3.00Buy$33.50120.11% UpsideMESOMesoblast 2.80Moderate Buy$24.0038.57% UpsideRXRXRecursion Pharmaceuticals 2.17Hold$7.2531.10% UpsideCurrent Analyst Ratings BreakdownLatest CMPX, RXRX, DNLI, and MESO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/6/2025CMPXCompass TherapeuticsCompass PointSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$10.0010/6/2025CMPXCompass TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.009/27/2025CMPXCompass TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025DNLIDenali TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MESOMesoblastWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025RXRXRecursion PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/11/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.009/8/2025DNLIDenali TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight8/18/2025DNLIDenali TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$33.00 ➝ $30.008/12/2025CMPXCompass TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.008/12/2025CMPXCompass TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $12.00(Data available from 10/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPXCompass TherapeuticsN/AN/AN/AN/A$0.91 per shareN/ADNLIDenali Therapeutics$330.53M6.73N/AN/A$8.53 per share1.78MESOMesoblast$17.20M128.89N/AN/A$4.67 per share3.71RXRXRecursion Pharmaceuticals$58.84M40.80N/AN/A$2.61 per share2.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPXCompass Therapeutics-$49.38M-$0.45N/AN/AN/AN/A-53.11%-46.14%11/11/2025 (Estimated)DNLIDenali Therapeutics-$422.77M-$2.80N/AN/AN/AN/A-40.79%-36.39%11/5/2025 (Estimated)MESOMesoblast-$102.14MN/A0.00N/AN/AN/AN/AN/AN/ARXRXRecursion Pharmaceuticals-$463.66M-$1.78N/AN/AN/A-1,004.91%-76.09%-54.29%11/5/2025 (Estimated)Latest CMPX, RXRX, DNLI, and MESO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025CMPXCompass Therapeutics-$0.13-$0.14-$0.01-$0.14N/AN/A8/11/2025Q2 2025DNLIDenali Therapeutics-$0.74-$0.72+$0.02-$0.72$5.64 millionN/A8/5/2025Q2 2025RXRXRecursion Pharmaceuticals-$0.35-$0.41-$0.06-$0.41$15.38 million$19.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMPXCompass TherapeuticsN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPXCompass TherapeuticsN/A7.667.66DNLIDenali Therapeutics0.0110.2710.27MESOMesoblast0.111.991.77RXRXRecursion Pharmaceuticals0.023.583.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPXCompass Therapeutics68.43%DNLIDenali Therapeutics92.92%MESOMesoblast1.43%RXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipCMPXCompass Therapeutics29.80%DNLIDenali Therapeutics12.50%MESOMesoblast18.80%RXRXRecursion Pharmaceuticals8.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPXCompass Therapeutics20138.28 million97.08 millionNot OptionableDNLIDenali Therapeutics430146.21 million127.94 millionOptionableMESOMesoblast80128.00 million103.93 millionOptionableRXRXRecursion Pharmaceuticals400434.15 million397.55 millionOptionableCMPX, RXRX, DNLI, and MESO HeadlinesRecent News About These CompaniesRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Consensus Recommendation of "Hold" from AnalystsOctober 3 at 10:51 PM | marketbeat.comRecursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains?October 3 at 10:56 AM | zacks.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 9.5% - What's Next?October 2, 2025 | marketbeat.comNeedham Reiterates a Buy on Recursion Pharmaceuticals (RXRX)September 30, 2025 | insidermonkey.comJim Cramer on Recursion: “I Need to See a Proof of Concept Here”September 29, 2025 | insidermonkey.comThe Biotech Stock That's Too Risky for Most InvestorsSeptember 28, 2025 | fool.comDoes Short Squeeze Attention and AI Advances Alter the Bull Case for Recursion Pharmaceuticals (RXRX)?September 27, 2025 | finance.yahoo.com10 Hidden-Gem AI Stocks to Buy Right NowSeptember 27, 2025 | fool.comPrediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From NowSeptember 26, 2025 | fool.comLooking for the Next Big Pop? Here’s Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat BounceSeptember 25, 2025 | msn.comRecursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's WhySeptember 22, 2025 | zacks.comRecursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 AdvancesSeptember 22, 2025 | finance.yahoo.comRecursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 AdvancesSeptember 21, 2025 | insidermonkey.comUBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Acquires 4,149,346 Shares of Recursion Pharmaceuticals, Inc. $RXRXSeptember 17, 2025 | marketbeat.comRecursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should KnowSeptember 16, 2025 | msn.comGoldman Sachs Group Inc. Has $7.91 Million Holdings in Recursion Pharmaceuticals, Inc. $RXRXSeptember 16, 2025 | marketbeat.comNeedham Retains Buy Rating on Recursion Pharmaceuticals, Maintains PT at $8September 15, 2025 | msn.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 8.7% Higher - Here's What HappenedSeptember 12, 2025 | marketbeat.comRecursion Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RXRX)September 12, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Receives "Buy" Rating from Needham & Company LLCSeptember 12, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. $RXRX Shares Purchased by Advisors Asset Management Inc.September 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMPX, RXRX, DNLI, and MESO Company DescriptionsCompass Therapeutics NASDAQ:CMPX$3.67 -0.03 (-0.81%) Closing price 04:00 PM EasternExtended Trading$3.66 -0.01 (-0.27%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Denali Therapeutics NASDAQ:DNLI$15.22 -0.20 (-1.30%) Closing price 04:00 PM EasternExtended Trading$15.37 +0.15 (+1.01%) As of 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Mesoblast NASDAQ:MESO$17.32 -1.09 (-5.92%) Closing price 04:00 PM EasternExtended Trading$17.34 +0.02 (+0.12%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Recursion Pharmaceuticals NASDAQ:RXRX$5.53 +0.04 (+0.73%) Closing price 04:00 PM EasternExtended Trading$5.55 +0.02 (+0.36%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Marvell Insiders Buy Shares—Should Investors Follow Suit? Behind D-Wave's Massive Week (And Why Rivals Also Popped) Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? Best Stocks Under $15? 3 Low-Priced Picks With Upside After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength Broadcom’s VMware Push Takes Aim at Microsoft, Google, & Amazon Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
